Attachment II - Page 3 
I! 
9209-026 (M) 
9209-027 (M) 
9209-028 (M) 
9209-029 (M) 
9209-030 (M) 
9209-031 (T) 
9209-032 (M) 
9209-033 (T) 
9212-034* (T) 
9212-035* (T) 
9212-036 (M) 
9303-037 (T) 
! 9303-038 (M) 
Walker, Robert E., National Institutes of Health, Bethesda, Maryland; A Study of the Safety and Survival of the Adoptive 
Transfer of Genetically Marked Syngeneic Lymphocytes in HTV Infected Identical Twins. 
RAC Approval: 9-14-92/NIH Approval: 9-3-93 
Schuening, Friedrich G., Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington; A Phase 
I /II Study of the Use of Recombinant Human Interleukin 3 (rhil3) Stimulated Peripheral Blood Progenitor Cell Supplementation In 
Autologous Bone Marrow Transplantation in Patients with Breast Carcinoma or Hodgkin 's Disease. 
RAC Approval: 9-14-92/NIH Approval: 2-5-93 
Schuening, Friedrich G., Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington; Evaluation 
of the Use of Recombinant Human G-CSF Stimulated Peripheral Blood Progenitor Cell Supplementation in Autologous Bone 
Marrow Transplantation in Patients with Lymphoid Malignancies. 
RAC Approval: 9-14-92/NIH Approval: 2-5-93 
Schuening, Friedrich G., Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington; A Trial of 
G-CSF Stimulated Peripheral Blood Stem Cells for Engraftmenl in Identical Twins. 
RAC Approval: 9-14-92/NIH Approval: 2-5-93 
Deisseroth. Albert B.. University of Texas MD Anderson Cancer Center. Houston. Texas: Use of Retroviral Markers to Identify 
Efficacy of Purging and Origin of Relapse Following Autologous Bone Marrow and Peripheral Blood Cell Transplantation in 
Indolent B Cell Neoplasms (Follicular Non-Hodgkin 's Lymphoma or Chronic Lymphocytic Leukemia) Patients. 
RAC Approval: 9-14-92 
Minor Modification: 11-3-93 
Minor Modification: 11-18-93 
Roth. Jack A.. The University of Texas MD Anderson Cancer Center. Houston. Texas: Clinical Protocol for Modification of 
Oncogene and Tumor Suppressor Gene Expression in Non-Small Cell Lung Cancer. 
RAC Approval: 9-15-92 
Brenner, Malcolm K., St Jude Children’s Research Hospital, Memphis, Tennessee; A Phase II Trial of the Baxter 
Neuroblastoma Bone Marrow Purging System Using Gene Marking to Assess Efficacy. 
RAC Approval: 9-15-92/NIH Approval: 2-5-93 
Lotze, Michael T. and Rubin, Joshua T., University of Pittsburgh, Pittsburgh, Pennsylvania; Gene Therapy of Cancer: A Pilot 
Study of IL-4 Gene Modified Antitumor Vaccines. 
RAC Approval: 9-15-92/NIH Approval: 2-5-93 
Crystal, Ronald G., National Institutes of Health, Bethesda, Maryland; A Phase I Study, in Cystic Fibrosis Patients, of the Safety, 
Toxicity, and Biological Efficacy of a Single Administration of a Replication Deficient, Recombinant Adenovirus Carrying the cDNA 
of the Normal Human Cystic Fibrosis Transmembrane Conductance Regulator Gene in the Lung. 
RAC Approval: 12-3-92/NIH Approval: 4-16-93 
Minor Modification: 5-17-93 
Minor Modification: 10-8-93 
Minor Modification: 11-29-93 
Wilson, James M., University of Pennsylvania, Philadelphia, Pennsylvania; Gene Therapy of Cystic Fibrosis Lung Diseases Using 
El Deleted Adenoviruses : A Phase I Trial. 
RAC Approval: 12-3-92/NIH Approval: 8-26-93 
Minor Modification: 8-17-93 
Welsh, Michael J., Howard Hughes Medical Institute, Iowa City, Iowa, and Smith, Alan E., Genzymc Corporation, 
Framingham, Massachusetts; Cystic Fibrosis Gene Therapy Using an Adenovirus Vector: In Vivo Safety and Efficacy in Nasal 
Epithelium. 
RAC Approval: 12-4-92/NIH Approval: 4-16-93 
Minor Modification: 10-18-93 
Culver, Kenneth W., Iowa Methodist Medical Center, Dcs Moines, Iowa, and Van Gilder, John G; University of Iowa, Iowa 
City, Iowa; Gene Therapy for the Treatment of Malignant Brain Tumors with In Vivo Tumor Transduction with the Herpes Simplex 
Thymidine Kinase Gene/Ganciclovir System. 
RAC Approval: 3-1-93/NIH Approval: 4-16-93 
Heslop, Helen E.; Brenner, Malcolm K.; and Rooney, Cliona, St Jude Children’s Research Hospital, Memphis, Tennessee; 
Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched -Related or 
PhenotypicaUy Similar Unrelated Donor Marrow Grcffts. 
RAC Approval: 3-2-93/NIH Approval: 4-16-93 
Recombinant DNA Research, Volume 18 
[575] 
